{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T20:08:15Z","timestamp":1776110895547,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["93-01-01-8106"],"award-info":[{"award-number":["93-01-01-8106"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00262-021-02889-5","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T08:02:53Z","timestamp":1615795373000},"page":"2961-2969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The impact of selenium on regulatory T cell frequency and immune checkpoint receptor expression in patients with\u00a0diffuse large B cell lymphoma (DLBCL)"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-0865","authenticated-orcid":false,"given":"Mehdi","family":"Dehghani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Negin","family":"Shokrgozar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mani","family":"Ramzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Kalani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Golmoghaddam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-0979","authenticated-orcid":false,"given":"Nargess","family":"Arandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"issue":"9844","key":"2889_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland KR, Armitage JO, Hancock BW (2012) Non-hodgkin lymphoma. Lancet 380(9844):848\u2013857","journal-title":"Lancet"},{"issue":"1","key":"2889_CR2","first-page":"618","volume":"2017","author":"SM Ansell","year":"2017","unstructured":"Ansell SM (2017) Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond. Hematol 2014 Am Soc Hematol Educ Prog Book 2017(1):618\u201321","journal-title":"Hematol 2014 Am Soc Hematol Educ Prog Book"},{"key":"2889_CR3","doi-asserted-by":"publisher","first-page":"1832968","DOI":"10.1155\/2017\/1832968","volume":"2017","author":"G D\u2019Arena","year":"2017","unstructured":"D\u2019Arena G, Vitale C, Coscia M, Festa A, Di Minno NMD, De Feo V et al (2017) Regulatory T Cells and their prognostic relevance in hematologic malignancies. J Immunol Res 2017:1832968","journal-title":"J Immunol Res"},{"issue":"34","key":"2889_CR4","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","volume":"24","author":"GJ Bates","year":"2006","unstructured":"Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL et al (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24(34):5373\u20135380","journal-title":"J Clin Oncol"},{"issue":"9","key":"2889_CR5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942","journal-title":"Nat Med"},{"issue":"3","key":"2889_CR6","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1158\/1078-0432.CCR-06-2363","volume":"13","author":"N Kobayashi","year":"2007","unstructured":"Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T et al (2007) FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13(3):902\u2013911","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2889_CR7","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00262-020-02591-y","volume":"69","author":"M Dehghani","year":"2020","unstructured":"Dehghani M, Kalani M, Golmoghaddam H, Ramzi M, Arandi N (2020) Aberrant peripheral blood CD4 (+) CD25 (+) FOXP3 (+) regulatory T cells\/T helper-17 number is associated with the outcome of patients with lymphoma. Cancer Immunol Immunother 69(9):1917\u20131928","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2889_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/ejh.12144","volume":"91","author":"M G\u0142owala-Kosi\u0144ska","year":"2013","unstructured":"G\u0142owala-Kosi\u0144ska M, Chwieduk A, Nieckula J, Sadu\u015b-Wojciechowska M, Grosicki S, Rusin A et al (2013) Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma. Eur J Haematol 91(2):122\u2013128","journal-title":"Eur J Haematol"},{"key":"2889_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.intimp.2018.05.025","volume":"61","author":"Z Cha","year":"2018","unstructured":"Cha Z, Gu H, Zang Y, Wang Z, Li J, Huang W et al (2018) The prevalence and function of CD4(+)CXCR5(+)Foxp3(+) follicular regulatory T cells in diffuse large B cell lymphoma. Int Immunopharmacol 61:132\u2013139","journal-title":"Int Immunopharmacol"},{"issue":"18","key":"2889_CR10","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-12-1972","volume":"19","author":"CJ Nirschl","year":"2013","unstructured":"Nirschl CJ, Drake CG (2013) Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 19(18):4917\u20134924","journal-title":"Clin Cancer Res"},{"key":"2889_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ (2018) Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 62:29\u201339","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"2889_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/phar.1643","volume":"35","author":"NM La-Beck","year":"2015","unstructured":"La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB (2015) Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacother J Hum Pharmacol Drug Ther 35(10):963\u201376","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"12","key":"2889_CR13","first-page":"6497","volume":"37","author":"SO Evans","year":"2017","unstructured":"Evans SO, Khairuddin PF, Jameson MB (2017) Optimising selenium for modulation of cancer treatments. Anticancer Res 37(12):6497\u20136509","journal-title":"Anticancer Res"},{"issue":"9822","key":"2889_CR14","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/S0140-6736(11)61452-9","volume":"379","author":"MP Rayman","year":"2012","unstructured":"Rayman MP (2012) Selenium and human health. Lancet 379(9822):1256\u20131268","journal-title":"Lancet"},{"issue":"5","key":"2889_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/bcpt.12207","volume":"114","author":"M Wallenberg","year":"2014","unstructured":"Wallenberg M, Misra S, Bj\u00f6rnstedt M (2014) Selenium cytotoxicity in cancer. Basic Clin Pharmacol Toxicol 114(5):377\u2013386","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"2889_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s13668-011-0003-x","volume":"1","author":"CD Davis","year":"2012","unstructured":"Davis CD (2012) Selenium supplementation and cancer prevention. Curr Nutr Rep 1(1):16\u201323","journal-title":"Curr Nutr Rep"},{"key":"2889_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2018.05.001","volume":"127","author":"V Gandin","year":"2018","unstructured":"Gandin V, Khalkar P, Braude J, Fernandes AP (2018) Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatment. Free Radic Biol Med 127:80\u201397","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"2889_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1385\/BTER:110:1:19","volume":"110","author":"IA Asfour","year":"2006","unstructured":"Asfour IA, El Shazly S, Fayek MH, Hegab HM, Raouf S, Moussa MA (2006) Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin\u2019s lymphoma patients. Biol Trace Elem Res 110(1):19\u201332","journal-title":"Biol Trace Elem Res"},{"issue":"3","key":"2889_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s12011-008-8240-6","volume":"127","author":"IA Asfour","year":"2009","unstructured":"Asfour IA, El-Tehewi MM, Ahmed MH, Abdel-Sattar MA, Moustafa NN, Hegab HM et al (2009) High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin\u2019s lymphoma. Biol Trace Elem Res 127(3):200","journal-title":"Biol Trace Elem Res"},{"issue":"1\u20133","key":"2889_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12011-007-0029-5","volume":"120","author":"IA Asfour","year":"2007","unstructured":"Asfour IA, Fayek M, Raouf S, Soliman M, Hegab HM, El-Desoky H et al (2007) The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin\u2019s lymphoma patients: correlation with response and survival. Biol Trace Elem Res 120(1\u20133):1\u201310","journal-title":"Biol Trace Elem Res"},{"issue":"9","key":"2889_CR21","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3390\/nu10091203","volume":"10","author":"JC Avery","year":"2018","unstructured":"Avery JC, Hoffmann PR (2018) Selenium, selenoproteins, and immunity. Nutrients 10(9):1203","journal-title":"Nutrients"},{"issue":"11","key":"2889_CR22","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mnfr.200700330","volume":"52","author":"PR Hoffmann","year":"2008","unstructured":"Hoffmann PR, Berry MJ (2008) The influence of selenium on immune responses. Mol Nutr Food Res 52(11):1273\u20131280","journal-title":"Mol Nutr Food Res"},{"issue":"7","key":"2889_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1089\/ars.2011.4145","volume":"16","author":"Z Huang","year":"2012","unstructured":"Huang Z, Rose AH, Hoffmann PR (2012) The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 16(7):705\u2013743","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"2889_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/archinternmed.2009.495","volume":"170","author":"JK MacFarquhar","year":"2010","unstructured":"MacFarquhar JK, Broussard DL, Melstrom P, Hutchinson R, Wolkin A, Martin C et al (2010) Acute selenium toxicity associated with a dietary supplement. Arch Intern Med 170(3):256\u2013261","journal-title":"Arch Intern Med"},{"issue":"4","key":"2889_CR25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1365-2141.2011.08744.x","volume":"154","author":"J Stevens","year":"2011","unstructured":"Stevens J, Waters R, Sieniawska C, Kassam S, Montoto S, Fitzgibbon J et al (2011) Serum selenium concentration at diagnosis and outcome in patients with haematological malignancies. Br J Haematol 154(4):448\u2013456","journal-title":"Br J Haematol"},{"issue":"12","key":"2889_CR26","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1200\/JCO.2003.06.145","volume":"21","author":"KW Last","year":"2003","unstructured":"Last KW, Cornelius V, Delves T, Sieniawska C, Fitzgibbon J, Norton A et al (2003) Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 21(12):2335\u20132341","journal-title":"J Clin Oncol"},{"issue":"21","key":"2889_CR27","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.3748\/wjg.v23.i21.3850","volume":"23","author":"L-X Sang","year":"2017","unstructured":"Sang L-X, Chang B, Zhu J-F, Yang F-L, Li Y, Jiang X-F et al (2017) Sodium selenite ameliorates dextran sulfate sodium-induced chronic colitis in mice by decreasing Th1, Th17, and \u03b3\u03b4T and increasing CD4 (+) CD25 (+) regulatory T-cell responses. World J Gastroenterol 23(21):3850","journal-title":"World J Gastroenterol"},{"issue":"7","key":"2889_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1507\/endocrj.K10E-063","volume":"57","author":"H Xue","year":"2010","unstructured":"Xue H, Wang W, Li Y, Shan Z, Li Y, Teng X et al (2010) Selenium upregulates CD4+ CD25+ regulatory T cells in iodine-induced autoimmune thyroiditis model of NOD. H-2h4 mice. Endocr J 57(7):595\u2013601","journal-title":"Endocr J"},{"issue":"10","key":"2889_CR29","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.3390\/ijms19103167","volume":"19","author":"RJ Lobb","year":"2018","unstructured":"Lobb RJ, Jacobson GM, Cursons RT, Jameson MB (2018) The interaction of selenium with chemotherapy and radiation on normal and malignant human mononuclear blood cells. Int J Mol Sci 19(10):3167","journal-title":"Int J Mol Sci"},{"key":"2889_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fonc.2018.00407","volume":"8","author":"D Nair","year":"2018","unstructured":"Nair D, R\u00e5destad E, Khalkar P, Diaz-Argelich N, Schr\u00f6der A, Klynning C et al (2018) Methylseleninic acid sensitizes ovarian cancer cells to T-cell mediated killing by decreasing PDL1 and VEGF levels. Front Oncol 8:407","journal-title":"Front Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02889-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-02889-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02889-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T13:06:32Z","timestamp":1631019992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-02889-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2889"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-02889-5","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"11 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed according to the ethical standards of the Ethical Committee of Shiraz University of Medical Sciences and in compliance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}